A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Completed · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
Key facts
- Study ID
- NCT02301117
- Run by
- Taiho Oncology, Inc.
- People needed
- 43
- Starts
- 2015-01-01
- Expected to finish
- 2019-06-19
- Last updated by the study team
- 2024-09-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Phoenix Clinical Site — Phoenix, Arizona, United States
- Duarte Clinical Site — Duarte, California, United States
- Santa Monica Clinical Site — Santa Monica, California, United States
- Gainesville Clinical Site — Gainesville, Florida, United States
- Baltimore Clinical Site — Baltimore, Maryland, United States
- Boston Clinical Site — Boston, Massachusetts, United States
- Cleveland Clinical Site — Cleveland, Ohio, United States
- Cleveland Clinical Site — Cleveland, Ohio, United States
- Pittsburgh Clinical Site — Pittsburgh, Pennsylvania, United States
- Dallas Clinical Site — Dallas, Texas, United States
- Brno Clinical Site — Brno, Czechia
- Praha Clinical Site — Prague, Czechia
- Belgrade Clinical Site — Belgrade, Serbia
- Sremska Kamenica Clinical Site — Kamenitz, Serbia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.